BioSpace News Archive

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced preliminary revenue results for the second quarter ending June 30, 2022 and updated its revenue guidance for 2022.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it entered into a clinical trial collaboration with Pharmacyclics, an AbbVie company, that includes supply of ibrutinib for its Phase 3 clinical trial.

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its first quarter ended June 30, 2022 after market close on August 4, 2022.

Elix, Inc., an AI drug discovery company with the mission of “Rethinking Drug Discovery” launched “Elix Discovery™,” the only all-in-one platform that provides everything needed for AI drug discovery, from models for property prediction and molecular design to AI consulting and implementation support.

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, has received IND clearance for the Company’s first cellular therapy product candidate addressing solid tumors.

Universal Health Services, Inc. (NYSE: UHS) announced today that it will report results for its second quarter ended June 30, 2022, after the market closes on Monday, July 25, 2022.

CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2022 financial and operating results after market close on Thursday, July 28th, 2022.

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares.

Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal Scientific Reports, entitled “Biometric and refractive changes following the monocular application of peripheral myopic defocus using a novel augmented-reality optical system in adults.”

Gestalt Diagnostics, Inc., a leading provider of digital pathology solutions, announces the availability of their Artificial Intelligence Requisition Engine (AIRE).